62 related articles for article (PubMed ID: 10836767)
21. [Interview with the author of ELITE II. Cave: small studies of fatal illnesses].
Pitt B
MMW Fortschr Med; 1999 Nov; 141(47):6. PubMed ID: 10912156
[No Abstract] [Full Text] [Related]
22. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.
Pitt B; Poole-Wilson PA; Segal R; Martinez FA; Dickstein K; Camm AJ; Konstam MA; Riegger G; Klinger GH; Neaton J; Sharma D; Thiyagarajan B
Lancet; 2000 May; 355(9215):1582-7. PubMed ID: 10821361
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological treatment and prevention of heart failure in the diabetic patient.
Nesto RW
Rev Cardiovasc Med; 2004; 5(1):1-8. PubMed ID: 15029109
[TBL] [Abstract][Full Text] [Related]
24. Prognostic benefit of beta-blockers in patients not receiving ACE-Inhibitors.
Krum H; Haas SJ; Eichhorn E; Ghali J; Gilbert E; Lechat P; Packer M; Roecker E; Verkenne P; Wedel H; Wikstrand J
Eur Heart J; 2005 Oct; 26(20):2154-8. PubMed ID: 16014644
[TBL] [Abstract][Full Text] [Related]
25. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT).
Reed SD; Friedman JY; Velazquez EJ; Gnanasakthy A; Califf RM; Schulman KA
Am Heart J; 2004 Jul; 148(1):122-8. PubMed ID: 15215801
[TBL] [Abstract][Full Text] [Related]
26. [Sartan as a new therapy option. When heart failure patients cannot tolerate an ACE inhibitor].
MMW Fortschr Med; 2002 Oct; 144(40):49. PubMed ID: 12440300
[No Abstract] [Full Text] [Related]
27. [ACE inhibitors and/or sartans in heart failure: is there a difference?].
Vachiéry JL
Rev Med Brux; 2003 Sep; 24(4):A249-52. PubMed ID: 14606288
[TBL] [Abstract][Full Text] [Related]
28. [New options against undertreatment].
Pfeffer M
MMW Fortschr Med; 2003 Dec; 145(49):18. PubMed ID: 14963987
[No Abstract] [Full Text] [Related]
29. [Effects of the long-term treatment with losartan and captopril and of the abrupt cessation on circadian blood pressure profile].
Gorbunov VM; Savina LV; Metelitsa VI; Deev AD
Eksp Klin Farmakol; 2001; 64(2):45-50. PubMed ID: 11548448
[TBL] [Abstract][Full Text] [Related]
30. Prospective and randomized study of the antihypertensive effect and tolerability of three antihypertensive agents, losartan, amlodipine, and lisinopril, in hypertensive patients.
Wu SC; Liu CP; Chiang HT; Lin SL
Heart Vessels; 2004 Jan; 19(1):13-8. PubMed ID: 14685749
[TBL] [Abstract][Full Text] [Related]
31. [Role of angiotensin-converting enzyme inhibitors in the treatment of heart failure in the 21st century].
Gibelin P
Arch Mal Coeur Vaiss; 2002 Feb; 95 Spec 4(5 Spec 4):41-5. PubMed ID: 11933555
[TBL] [Abstract][Full Text] [Related]
32. A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications.
Ahmed A; Centor RM; Weaver MT; Perry GJ
Am Heart J; 2005 Apr; 149(4):737-43. PubMed ID: 15990761
[TBL] [Abstract][Full Text] [Related]
33. Angiotensin II receptor antagonists for heart failure.
Struthers AD
Heart; 1998 Jul; 80(1):5-6. PubMed ID: 9764049
[No Abstract] [Full Text] [Related]
34. Comparison of losartan and captopril in ELITE II.
Hall A
Lancet; 2000 Sep; 356(9232):851; author reply 852-3. PubMed ID: 11022946
[No Abstract] [Full Text] [Related]
35. Losartan as an alternative to ACE inhibitors in patients with renal dysfunction.
Esmail ZN; Loewen PS
Ann Pharmacother; 1998 Oct; 32(10):1096-8. PubMed ID: 9793603
[TBL] [Abstract][Full Text] [Related]
36. The ELITE Study. What are its implications for the drug treatment of heart failure? Evaluation of Losartan in the Elderly Study.
Aronow WS
Drugs Aging; 1998 Jun; 12(6):423-8. PubMed ID: 9638391
[TBL] [Abstract][Full Text] [Related]
37. [Blocker of angiotensin-1 receptor antagonist losartan. Part III. Experience in therapy for chronic heart failure and after acute myocardial infarction].
Sidorenko BA; Preobrazhenskiĭ DV; Stetsenko TM; Tarykina EV; Tsurko VV
Kardiologiia; 2003; 43(3):93-8. PubMed ID: 12891263
[TBL] [Abstract][Full Text] [Related]
38. Shifts in mortality curves.
Brotheridge SP
Lancet; 1999 Dec 18-25; 354(9196):2169. PubMed ID: 10609850
[No Abstract] [Full Text] [Related]
39. Does losartan decrease all-cause mortality more than placebo or first-generation ACE inhibitors for patients with moderate to severe heart failure?
LeClair BM
J Fam Pract; 2000 May; 49(5):397. PubMed ID: 10836767
[No Abstract] [Full Text] [Related]
40. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
